Dermtech Inc (DMTK)

$0.1455

-0.19

(-56.24%)

Market is closed - opens 7 PM, 20 Jun 2024

Insights on Dermtech Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.92M → 3.84M (in $), with an average decrease of 2.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -19.09M → -20.01M (in $), with an average decrease of 4.8% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 8.8% return, outperforming this stock by 96.8%

  • Vs TMO

    In the last 3 years, Dermtech Inc has experienced a drawdown of -99.3%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 90.2%

Performance

  • $0.11
    $0.17
    $0.15
    downward going graph

    26.67%

    Downside

    Day's Volatility :34.87%

    Upside

    11.19%

    downward going graph
  • $0.15
    $3.90
    $0.15
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :96.15%

    Upside

    96.15%

    downward going graph

Returns

PeriodDermtech IncSector (Health Care)Index (Russel 2000)
3 Months
-49.8%
0.6%
0.0%
6 Months
-77.98%
8.9%
0.0%
1 Year
-87.26%
10.2%
0.0%
3 Years
-99.25%
17.8%
-20.9%

Highlights

Market Capitalization
11.1M
Book Value
$1.14
Earnings Per Share (EPS)
-2.65
Wall Street Target Price
2.04
Profit Margin
0.0%
Operating Margin TTM
-533.37%
Return On Assets TTM
-38.6%
Return On Equity TTM
-121.75%
Revenue TTM
15.7M
Revenue Per Share TTM
0.47
Quarterly Revenue Growth YOY
10.6%
Gross Profit TTM
647.0K
EBITDA
-84.7M
Diluted Eps TTM
-2.65
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.99
EPS Estimate Next Year
-2.08
EPS Estimate Current Quarter
-0.57
EPS Estimate Next Quarter
-0.51

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Dermtech Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
9
9
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1302.06%

Current $0.15
Target $2.04

Technicals Summary

Sell

Neutral

Buy

Dermtech Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dermtech Inc
Dermtech Inc
-7.66%
-77.98%
-87.26%
-99.25%
-96.79%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.86%
-6.6%
4.59%
-16.09%
86.98%
Agilent Technologies Inc.
Agilent Technologies Inc.
-14.75%
-4.14%
11.57%
-9.09%
83.33%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.38%
9.52%
7.7%
17.73%
96.4%
Danaher Corp.
Danaher Corp.
-4.86%
12.22%
7.41%
-1.11%
80.22%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-7.29%
-5.6%
-0.75%
-10.99%
46.45%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dermtech Inc
Dermtech Inc
NA
NA
NA
-1.99
-1.22
-0.39
NA
1.14
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.79
48.79
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
30.94
30.94
2.7
5.23
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.62
36.62
2.81
21.72
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
46.76
46.76
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.14
29.14
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dermtech Inc
Dermtech Inc
Buy
$11.1M
-96.79%
NA
0.0%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.6B
86.98%
48.79
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.1B
83.33%
30.94
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$218.4B
96.4%
36.62
14.2%
Danaher Corp.
Danaher Corp.
Buy
$188.8B
80.22%
46.76
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$38.9B
46.45%
29.14
9.01%

Institutional Holdings

  • Vanguard Group Inc

    3.98%
  • BlackRock Inc

    1.24%
  • Hongkou Capital LP

    1.18%
  • Geode Capital Management, LLC

    0.88%
  • Texas Capital Bank Wealth Management Services Inc

    0.57%
  • King Luther Capital Management Corp

    0.53%

Company Information

dermtech is a molecular diagnostic dermatology company focused on developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. dermtech operates a clia (clinical laboratory improvement amendments) licensed laboratory located at the company’s la jolla, ca headquarters. dermtech’s technology allows for the analysis of skin biopsy samples collected non-invasively using an adhesive patch. current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. dermtech’s pigmented lesion assay (pla) provides physicians with a non-invasive option for the biopsy of clinically atypical pigmented lesions using an adhesive patch rather than a scalpel. dermtech provides highly accurate, objective information to the physician to improve patient care and comfort and reduce costs. the pla is used for the detection of melanoma in at

Organization
Dermtech Inc
Employees
206
CEO
Mr. Kevin Sun M.B.A.
Industry
Finance

FAQs